Dengue: Difference between revisions
Line 37: Line 37:
**See [[Fever in traveler]]
**See [[Fever in traveler]]
*Definitive Dengue testing
*Definitive Dengue testing
**Acute phase (0-7 days post symptom onset)
**Acute phase (0-7 days post symptom onset)<ref>https://www.cdc.gov/dengue/hcp/diagnosis-testing/index.html</ref>
***A nucleic acid amplification test (NAAT) (e.g., RT-PCR) AND an IgM antibody test, OR
***A nucleic acid amplification test (NAAT) (e.g., RT-PCR) AND an IgM antibody test, OR
***A NS1 ELISA test AND an IgM detection test
***A NS1 ELISA test AND an IgM detection test
**Convalescent Phase (>7 days post symptom onset)
**Convalescent Phase (>7 days post symptom onset)
**Reverse transcription polymerase chain reaction (RT-PCR) OR non-structural protein 1 (NS1) antigen tests, AND
***IgM antibody (primary test)
**IgM antibody tests
****Can be reliably detected 3 months or longer after infection
**For public health purposes, these tests may be ordered regardless of time since symptom onset
**For public health purposes, these tests may be ordered regardless of time since symptom onset
*Concern for Severe Dengue
*Concern for Severe Dengue
Line 50: Line 50:
[[File:Dengue testing.png|thumb|When laboratory tests become positive. Day zero is symptom start. 1st = primary infection; 2nd = secondary infection.<ref>Simmons CP, Farrar JJ, Nguyen vV, Wills B (April 2012). "Dengue" (PDF). The New England Journal of Medicine. 366 (15): 1423–32. doi:10.1056/NEJMra1110265. hdl:11343/191104. PMID 22494122. Archived from the original on 28 August 2021. Retrieved 24 September 2019.</ref>]]
[[File:Dengue testing.png|thumb|When laboratory tests become positive. Day zero is symptom start. 1st = primary infection; 2nd = secondary infection.<ref>Simmons CP, Farrar JJ, Nguyen vV, Wills B (April 2012). "Dengue" (PDF). The New England Journal of Medicine. 366 (15): 1423–32. doi:10.1056/NEJMra1110265. hdl:11343/191104. PMID 22494122. Archived from the original on 28 August 2021. Retrieved 24 September 2019.</ref>]]
*Typically a clinical diagnosis in the ED
*Typically a clinical diagnosis in the ED
**All patients with clinically suspected dengue should receive appropriate management without waiting for diagnostic test results.
*Definitive testing
*Definitive testing
**IgM diagnosed by a 4x increase in acute/ convalescent titers
**IgM diagnosed by a 4x increase in acute/ convalescent titers
Line 60: Line 61:
**Hemorrhage
**Hemorrhage
**[[Respiratory distress]]
**[[Respiratory distress]]
A positive NAAT test does not require further confirmatory testing.
The presence of the dengue virus non-structural protein 1 (NS1) in blood (serum) during the first 7 days of illness is indicative of a current or recent dengue virus infection. Indications for use of commercial NS1 ELISA tests, and interpretation of positive NS1 ELISA test results may vary.
A negative result from a RT-PCR or NS1 ELISA test does not rule out infection.
A positive result by RT-PCR or NS1 ELISA meets the confirmatory laboratory criteria for diagnosis in the National Notifiable Diseases Surveillance System (NNDSS) dengue case definition.


===Tourniquet Test===
===Tourniquet Test===

Revision as of 17:51, 16 April 2025

Background

World map highlighting areas of dengue risk.[1]
Femail Ades aegypti mosquito feeding on a person.
  • A viral infection transmitted though Aedes mosquitos typically in urban areas, especially during rainy seasons in tropical/subtropic regions (Asia, Africa, Central America, Caribbean)
    • Los Angeles County reported 14 confirmed cases of locally acquired dengue in 2024[2]
  • Also known as "break-bone fever"
  • Most infections are asymptomatic or produce only mild illness, but the virus occasionally causes more severe cases up to death (i.e., "severe dengue")[3]
    • Severe dengue (which includes "dengue shock syndrome") is rare in travelers, as it is cause by a second infection of a different Dengue serotype (so patients must have had two separate exposures at different times to be at risk)

Clinical Features

Clinical course of dengue fever.
Early dengue rash.
Recover phase rash: classic islands of white in a sea of red.

Dengue

  • Incubation 3-7 days
  • Febrile phase:
    • High fever + "Break-bone" pain + GI symptoms + rash + possible exposure
    • +/- Faget sign
    • Lasts 3-7 days, majority recover

Severe Dengue

As above, followed by:

  • Critical Phase[4]:
    • Minority of patients, generally pediatric and elderly
    • Around time of defervescence
    • Vascular leak, hypoproteinemia, hemoconcentration, pleural effusion, ascites
    • Narrowed pulse pressure, persistent vomiting, RUQ tenderness, lethargy and restlessness are signs of impending collapse
    • Mucosal and skin bleeding

Differential Diagnosis

Fever in traveler

Evaluation

Work-up

  • Consider tests to rule out other possible processes:
  • Definitive Dengue testing
    • Acute phase (0-7 days post symptom onset)[5]
      • A nucleic acid amplification test (NAAT) (e.g., RT-PCR) AND an IgM antibody test, OR
      • A NS1 ELISA test AND an IgM detection test
    • Convalescent Phase (>7 days post symptom onset)
      • IgM antibody (primary test)
        • Can be reliably detected 3 months or longer after infection
    • For public health purposes, these tests may be ordered regardless of time since symptom onset
  • Concern for Severe Dengue

Diagnosis

When laboratory tests become positive. Day zero is symptom start. 1st = primary infection; 2nd = secondary infection.[6]
  • Typically a clinical diagnosis in the ED
    • All patients with clinically suspected dengue should receive appropriate management without waiting for diagnostic test results.
  • Definitive testing
    • IgM diagnosed by a 4x increase in acute/ convalescent titers
  • Other possible lab findings:
  • Severe Dengue if any of the following identified:

A positive NAAT test does not require further confirmatory testing. The presence of the dengue virus non-structural protein 1 (NS1) in blood (serum) during the first 7 days of illness is indicative of a current or recent dengue virus infection. Indications for use of commercial NS1 ELISA tests, and interpretation of positive NS1 ELISA test results may vary. A negative result from a RT-PCR or NS1 ELISA test does not rule out infection. A positive result by RT-PCR or NS1 ELISA meets the confirmatory laboratory criteria for diagnosis in the National Notifiable Diseases Surveillance System (NNDSS) dengue case definition.


Tourniquet Test

Example of positive tourniquet test (right arm).
  • Tests for capillary fragility as a sign of Severe Dengue
  • Typically used in the absence of available DIC labs (i.e., low-resource settings)
    • Sensitivity of 52% and specificity of 82.4%
    • A positive tourniquet test combined with lekuopenia increases sensitivity to 94%[7]
    • Inflate cuff to pressure between SBP & DBP, and leave for 5 min
    • (+) Test = 10-20 petechiae per square inch

Management

Dengue

Severe Dengue

Above plus:

Disposition

Dengue

  • Typically outpatient, if well hydrated and non-toxic appearing
  • May consider admitting certain high-risk patients (e.g., pregnant, extremes of age, concerning concomitant chronic disease)

Severe Dengue

  • Typically admitted
    • Consider ICU admission for patients with shock and end-organ damage

Prevention

  • The vaccine Dengvaxia was approved by the Food and Drug Administration in 2021 and was recommended for children and adolescents aged 9 – 16 years who had a laboratory confirmed previous dengue virus infection AND live in areas where dengue is common. However, production of this product was discontinued due to low demand and currently, no vaccines are available.[8][9][10].

See Also

References

  1. ↑ CDC. July, 2024. https://www.cdc.gov/dengue/areas-with-risk/?CDC_AAref_Val=https://www.cdc.gov/dengue/areaswithrisk
  2. ↑ http://publichealth.lacounty.gov/acd/VectorDengue.htm
  3. ↑ WHO website. https://www.who.int/news-room/fact-sheets/detail/dengue-and-severe-dengue#:~:text=There%20is%20no%20specific%20treatment%20for%20dengue.,often%20used%20to%20control%20pain.
  4. ↑ Simmons, C.P., Farrar, J.J., van Vinh Chau, N. and Wills, B. (2012) ‘Dengue’, New England Journal of Medicine, 366(15), pp. 1423–1432.
  5. ↑ https://www.cdc.gov/dengue/hcp/diagnosis-testing/index.html
  6. ↑ Simmons CP, Farrar JJ, Nguyen vV, Wills B (April 2012). "Dengue" (PDF). The New England Journal of Medicine. 366 (15): 1423–32. doi:10.1056/NEJMra1110265. hdl:11343/191104. PMID 22494122. Archived from the original on 28 August 2021. Retrieved 24 September 2019.
  7. ↑ Gregory CJ, Lorenzi OD, Colón L, García AS, Santiago LM, Rivera RC, Bermúdez LJ, Báez FO, Aponte DV, Tomashek KM, Gutierrez J, Alvarado L. Utility of the tourniquet test and the white blood cell count to differentiate dengue among acute febrile illnesses in the emergency room. PLoS Negl Trop Dis. 2011 Dec;5(12):e1400.
  8. ↑ Paz-Bailey G, Adams L, Wong JM, et al. Dengue Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021. MMWR Recomm Rep 2021;70(No. RR-6):1–16. DOI: http://dx.doi.org/10.15585/mmwr.rr7006a1
  9. ↑ http://publichealth.lacounty.gov/acd/VectorDengue.htm
  10. ↑ Paz-Bailey G, Adams L, Wong JM, et al. Dengue Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021. MMWR Recomm Rep 2021;70(No. RR-6):1–16. DOI: http://dx.doi.org/10.15585/mmwr.rr7006a1
Retrieved from "https://www.wikem.org/w/index.php?title=Dengue&oldid=376170"